^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Esophageal Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers: Useful in Certain Circumstances...Pembrolizumab for TMB high (≥10 mutations/megabase) tumors…
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Effect of multi-omics analysis on tumor ecosystem during neoadjuvant dose-limiting chemotherapy combination with sequential PD-1 blockade for patients with esophageal cancer.

    Published date:
    05/25/2023
    Excerpt:
    A study on 23 enrolled patients with esophageal cancer who received 2 cycles of neoadjuvant treatment of dose-limiting chemotherapy combined with sequential pembrolizumab...After neoadjuvant therapy, the percentage of patients with a pathological major response (MPR) was 39.1% (9/23), consisting of 21.7% (5/23) completed pathological response (cPR)...Tumor mutational burden (TMB) was higher in the MPR group than in the non-MPR group at baseline...Additionally, TMB, CD8+ T cells, and Treg cells are associated with clinical benefits during treatment.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1200/JCO.2023.41.16_suppl.e16085